Assessing the impacts of phosphorus inactive clay on phosphorus release control and phytoplankton community structure in eutrophic lakes.

Addressing the challenge that phosphorus is the key factor and cause for eutrophication, we evaluated the phosphorus release control performance of a new phosphorus inactive clay (PIC) and compared with Phoslock®. Meanwhile, the impacts of PIC and Phoslock® on phytoplankton abundance and community structure in eutrophic water were also discussed. With the dosage of 40 mg/L, PIC effectively removed 97.7% of total phosphorus (TP) and 98.3% of soluble reactive phosphorus (SRP) in eutrophic waters. In sediments, Fe/Al-phosphorus and organic phosphorus remained stable whereas Ca-phosphorus had a significant increase of 13.1%. The results indicated that PIC may form the active overlay at water-sediment interface and decrease the bioavailability of phosphorus. The phytoplankton abundance was significantly reduced by PIC and decreased from (1.0-2.4) × 107 cells/L to (1.3-4.3) × 106 cells/L after 15 d simultaneous experiment. The phytoplankton community structure was also altered, where Cyanobacteria and Bacillariophyceae were the most inhibited and less dominant due to their sensitivity to phosphorus. After PIC treatment, the residual lanthanum concentration in water was 1.44-3.79 µg/L, and the residual aluminium concentration was low as 101.26-103.72 µg/L, which was much less than the recommended concentration of 200 µg/L. This study suggests that PIC is an appropriate material for phosphorus inactivation and algal bloom control, meaning its huge potential application in eutrophication restoration and management.

An alternative mebendazole formulation for cystic echinococcosis: the treatment efficacy, pharmacokinetics and safety in mice.

BACKGROUND: Cystic echinococcosis is a serious zoonotic infection worldwide caused by metacestodes of Echinococcus gruanulosus. Mebendazole and albendazole are the only two drugs used in the treatment of this disease with cure rates only about 30% due to the poor oral absorption. Thus an alternative treatment for this disease is needed. METHODS: A mebendazole oily suspension (MBZ-OS) was prepared and orally administrated to mice infected with echinococcus cysts for 8 months at 12.5 mg/kg and 25 mg/kg for 14 consecutive days. Mebendazole suspended in 1% tragacanth (MBZ-1% tragacanth) served as treated control. In addition, liver and serum samples were collected from these treated mice (25 mg/kg) for histopathology examination and liver function test. For pharmacokinetic analysis, plasma, parasite (cyst wall and cyst fluid) and tissue samples were collected at 0.25, 0.5, 1, 2, 4, 8, 16 and 24 h after orally administrating MBZ-OS and MBZ-1% tragacanth to E. granulosus-infected mice at 25 mg/kg. These samples were then processed and quantitatively analyzed by HPLC. RESULTS: The administration of MBZ-OS resulted in a treatment efficacy with the cyst weight reductions higher than 80%, significantly better than the corresponding MBZ-1% tragacanth groups. The better treatment efficacy of MBZ-OS was related to the higher drug concentration in plasma, parasites and tissues. It was also shown that the injury of the liver was not significantly altered by taking MBZ-OS compared to the untreated control. CONCLUSION: These findings demonstrate that MBZ-OS is a promising new formulation of MBZ for treatment of hydatid diseases without showing significantly liver toxicity.

Coelomycin, a highly substituted 2,6-dioxo-pyrazine fungal metabolite antibacterial agent discovered by Staphylococcus aureus fitness test profiling.

Bacterial resistance to antibiotics, particularly to multiple antibiotics, is becoming a cause for significant concern. The only really viable course of action to counter this is to discover new antibiotics with novel modes of action. We have recently implemented a new antisense-based chemical genetic screening technology to accomplish this goal. The discovery and antibacterial activity of coelomycin, a fully substituted 2,6-dioxo pyrazine, illustrates the application of the Staphylococcus aureus fitness test strategy to natural products discovery.

Tenellones A and B from a Diaporthe sp.: two highly substituted benzophenone inhibitors of parasite cGMP-dependent protein kinase activity.

Parasite cGMP-dependent protein kinase (PKG) has been recently validated as a biochemical target for the treatment of coccidiosis. To discover new anticoccidial leads, we have screened our library of natural product extracts for inhibitors of parasite PKG. Bioassay-guided fractionation of the microbial extracts has led to the discovery of tenellones A (2) and B (3), two new highly substituted benzophenones. The isolation, structure, and activity of these compounds are described.